1,148 filings
Page 3 of 58
SD
tjexn64xp0
31 May 23
Conflict minerals disclosure
4:01pm
UPLOAD
xv3squfwnhqr3
22 May 23
Letter from SEC
12:00am
20-F/A
0cig0jmkrvz
15 May 23
Annual report (foreign) (amended)
4:40pm
CORRESP
tkz61v03nyvt3fn bj
9 May 23
Correspondence with SEC
12:00am
6-K
zmb7vnhdpnwbz483u6k1
25 Apr 23
Current report (foreign)
7:30am
UPLOAD
af8gt5wd51l9
25 Apr 23
Letter from SEC
12:00am
6-K
5mnnj7
27 Mar 23
Current report (foreign)
8:14am
S-8 POS
dijxn 30fuo0trcb3d
24 Mar 23
Registration of securities for employees (post-effective amendment)
5:00pm
6-K
fynv i6tsqzz
1 Feb 23
Current report (foreign)
7:55am
6-K
q1td5gym3
1 Feb 23
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
7:53am
IRAN
b6c 5lt1uz4b24cs0
1 Feb 23
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
7:51am
S-8 POS
ik6c1l k2wqx
10 Jan 23
Registration of securities for employees (post-effective amendment)
4:30pm
F-6 POS
esyyhcc uk3ss3
16 Dec 22
Automatic registration for ADRs (post-effective amendment, foreign)
3:42pm
6-K
sasaq3kgn0fhx8
5 Dec 22
Current report (foreign)
9:27am
6-K
29rkjt
25 Oct 22
Current report (foreign)
9:40am
6-K
rf68q1kvw22jfnge
24 Oct 22
Current report (foreign)
6:05am
6-K
5v0yu uy41ispq5
21 Sep 22
Current report (foreign)
6:05am
6-K
d5cvf269
25 Aug 22
Current report (foreign)
8:58am
6-K
f60r6fg65
19 Jul 22
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
6:49am